Iovance Biotherapeutics, Inc. (IOVA)

NASDAQ: IOVA · Real-Time Price · USD

8.08

-0.09 (-1.10%)

At close: Nov 10, 2026, 4:00 PM EST

8.10

+0.02 (0.23%)

After-hours: Nov 10, 2026, 6:22 PM EST

Iovance Biotherapeutics Financials Overview

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep '26 Sep 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	378.98	263.5	164.07	1.19	-	-
Revenue Growth	51.34%	60.60%	13698.99%	-	-	-
Gross Profit	201.75	90.32	70.82	0.16	-	-
Operating Income	-230.38	-398.21	-395.28	-460.56	-398.88	-342.7
Net Income	-220.54	-390.98	-372.18	-444.04	-395.89	-342.25
Earnings Per Share	-0.51	-1.09	-1.28	-1.89	-2.49	-2.23
EPS Growth	-	-	-	-	-	-

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023
Period Ending	Sep '26 Sep 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023
Amtagvi	317.44	220.02	103.57	-
Proleukin	61.54	43.48	60.5	1.19
Revenue (Total)	378.98	263.5	164.07	1.19

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep '26 Sep 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Investments	376.32	296.98	323.78	279.87	471.85	504.41
Total Debt	45.21	49.44	58.26	75.86	85.45	71.53
Net Cash (Debt)	331.11	247.54	265.52	204.01	386.4	432.88
Net Cash Growth	33.34%	-6.77%	30.15%	-47.20%	-10.74%	-25.08%
Net Cash Per Share	0.76	0.69	0.92	0.87	2.43	2.82

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep '26 Sep 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Operating Cash Flow	-189.95	-302.41	-352.98	-361.82	-292.76	-227.94
Capital Expenditures	-26.11	-33.84	-11.07	-22.29	-20.43	-37.57
Free Cash Flow	-216.06	-336.24	-364.05	-384.11	-313.18	-265.52
Free Cash Flow Growth	-	-	-	-	-	-

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep '26 Sep 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Gross Margin	53.23%	34.28%	43.17%	13.12%	-	-
Operating Margin	-60.79%	-151.12%	-240.92%	-38734.99%	-	-
Pretax Margin	-58.52%	-149.16%	-228.56%	-37638.02%	-	-
Profit Margin	-58.19%	-148.38%	-226.84%	-37345.42%	-	-
FCF Margin	-57.01%	-127.61%	-221.89%	-32305.30%	-	-

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Nov '26 Nov 10, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
PS Ratio	9.87	4.11	13.75	1749.89	-	-